While initially introduced as a treatment for type-2 diabetes, patients taking glucagon-like peptide 1 (GLP-1) receptor agonists (see Text Box 1) found a discrete change in the amount and types of food they desire, including the curbing of cravings for certain less nutritious categories of foods (e.g., sweets, fried foods), which helped patients who were overweight or obese lose clinically significant amounts of weight and, with continued use, to maintain weights 15%20% lower than premedication levels (Rubino et al., 2021, Aronne et al., 2024)
High dose statin treatment reduces circulating Dickkopf-1 following acute myocardial infarction
10.1371/journal.pone.0097554 38 KristensenS
Pancreatic -cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation
The last 3 days, Im buying real groceries